New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 19, 2014
08:06 EDTEXASExact Sciences announces DeeP-C study results published
Exact Sciences announced that results from its DeeP-C clinical study have been published online in the New England Journal of Medicine. The peer-reviewed study, “Multi-target Stool DNA Testing for Colorectal-Cancer Screening” will also appear in the journal’s April 3 print issue. The company said, "In our clinical study, the data show that Cologuard, the multi-target stool-based DNA test, is highly sensitive in detecting colorectal cancer and higher risk pre-cancerous polyps in a large, diverse average-risk patient population and has the potential to be an important screening tool.” The Exact Sciences Cologuard screening test is an investigational device currently under review by the U.S. Food and Drug Administration and is not available for sale in the U.S. The FDA’s Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee is scheduled to review Exact Science’s PMA application for Cologuard on March 27.
News For EXAS From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 30, 2015
10:52 EDTEXASLeerink's life science tools analyst holds an analyst/industry conference call
Subscribe for More Information
08:05 EDTEXASExact Sciences says Tufts Health Plan to cover Cologuard
Subscribe for More Information
March 26, 2015
10:04 EDTEXASOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
09:23 EDTEXASOn The Fly: Pre-market Movers
Subscribe for More Information
06:07 EDTEXASExact Sciences downgraded to Neutral from Buy at Goldman
Goldman downgraded Exact Sciences to Neutral to reflect lower revenue estimates for Cologuard adoption. Price target lowered to $24 from $29.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use